Join the Department of Infectious Disease for the next Infection Rounds event, featuring talks on meningococcal infection and Imperial’s self-amplifying RNA vaccine for COVID-19.
Infection Rounds bring together clinicians and scientists working in infectious disease to discuss clinical cases and the latest scientific developments.
All are welcome to join us via Teams on 21 October, 16:00-17:00, to hear two fascinating talks:
Dr Ravi Mehta – ‘Meningococcal infection : An unusual cause of chest pain’
Dr Ravi Mehta is a Specialist Registrar and Academic Clinical Fellow in Infectious Diseases at Imperial College. He is currently working on applying metabolomics to discover novel serum and urinary biomarkers of infectious diseases. Previously, he worked as a Clinical Research Fellow in Rio de Janeiro, Brazil, investigating the seroprevalence and adult neurological complications of Zika and chikungunya viruses.
Dr Mehta’s talk will focus on a case report of a patient admitted to Hammersmith Hospital with a rare cardiac presentation of infection with Neisseria meningitidis.
Dr Katrina Pollock – ‘A self-amplifying RNA vaccine against SARS-CoV-2; pushing the boundaries of vaccinology’
Dr Katrina Pollock is a Senior Clinical Research Fellow in Vaccinology and Honorary Consultant at Imperial College London. She is Chief Investigator for the Imperial COVID-19 RNA vaccine trials and Principle Investigator for the Oxford COVID-19 vaccine trials. She read medicine as an undergraduate at Newnham College, University of Cambridge, and then at Imperial College School of Medicine before completing speciality training as a clinician scientist in genitourinary and HIV medicine. She now leads a series of experimental medicine, early phase and first-in-human trials supporting the development of novel vaccines against a broad variety of pathogens including HIV, chlamydia, Ebola, malaria and most recently SARS-CoV-2 infection.
Dr Pollock’s talk will cover the Imperial self-amplifying RNA vaccine programme, which is developing a platform technology for public health security and demonstrate the translation of the Imperial COVID-19 saRNA vaccine from laboratory to first-in-human clinical trials.